People · Operator

David Scott Grayzel

Named in public records as an officer, director or promoter · active 2023–2023 · Pharmaceuticals

1
Companies
1
Filings
$73.6M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Comanche Biopharma Corp.PharmaceuticalsSeries B$73.6M$325.9M2023
Operator network

David Scott Grayzel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Michael Scott Young · 2 companies · 1 sharedMichael Scott You…Paul Scott Antinori · 2 companies · 1 sharedPaul Scott Antino…Allison Scott August · 1 companies · 1 sharedAllison Scott Aug…Allyson Scott Felix · 1 companies · 1 sharedAllyson Scott Fel…Ann Scott Taylor · 1 companies · 1 sharedAnn Scott TaylorArthur Scott Levin · 1 companies · 1 sharedArthur Scott LevinBrendan Scott Bulik-Sullivan · 1 companies · 1 sharedBrendan Scott Bul…Clive Scott Meanwell · 1 companies · 1 sharedClive Scott Meanw…Ketan Scott Patel · 1 companies · 1 sharedKetan Scott PatelMuzammil Scott Mansuri · 1 companies · 1 sharedMuzammil Scott Ma…Scott Scott Gottlieb · 1 companies · 1 sharedScott Scott Gottl…Thomas Scott Johnson · 1 companies · 1 sharedThomas Scott John…Comanche Biopharma Corp. · $73.6M raisedComanche Biopharma Co…David Scott GrayzelDG
David Scott Grayzel Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside David Scott Grayzel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Paul Scott Antinori12
Michael Scott Young12
Muzammil Scott Mansuri11
Allison Scott August11
Allyson Scott Felix11
Thomas Scott Johnson11
Scott Scott Gottlieb11
Ketan Scott Patel11
Arthur Scott Levin11
Ann Scott Taylor11
Clive Scott Meanwell11
Brendan Scott Bulik-Sullivan11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.